References

Bolten, B.M. and DeGregorio, T. (2002) Trends in development cycles. Nature Reviews Drug Discovery 1, 335-336.

Chanda, S.K. and Caldwell, J.S. (2003) Fulfilling the promise: drug discovery in the post-genomic area. Drug Discovery Today 8, 168-174.

DiMasi, J.A., Hansen, R.W. and Grabowski, H.G. (2003) The price of innovation: new estimates of drug development costs. J. Health Economics 22, 151-185.

Drews, J. (2000) Drug Discovery: a historical perspective. Science 287, 1960-1964.

FDA (2004) Innovation and Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. FDA White Paper.

Handen, J.S. (2002) The industrialization of drug discovery. Drug Discovery Today 7, 83-85.

Kola, I. And Landis, J. (2004) Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discovery 3, 711-715.

Lindsay, M.A. (2003) Target discovery. Nature Reviews Drug Discovery 2, 831-838.

Nature Insight: Chemical Space (2004) Nature 432, 824-865.

Sams-Dodd, Frank (2005) Target-based drug discovery: is something wrong? Drug Discovery Today 10, 139-147.

Related Web Sites

FDA Center for Drug Evaluation and Research
Tufts Center for the Study of Drug Development
ClinicalTrials.gov